← All trials
NCT04286503
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 23, 2020
- Primary completion
- Feb 28, 2021
- Completion date
- Feb 28, 2021
- First posted
- Feb 27, 2020
- Last posted
- Feb 27, 2020
- Enrollment
- 520
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Capital Medical UniversityLead sponsor
- Chongqing Medical UniversityCollaborator
- Harbin Medical UniversityCollaborator
- Wuhan UniversityCollaborator
- Capital Medical UniversityReponsible party - principal investigator
- Capital Medical UniversityOverall official - principal investigator
- Bengbu Medical CollegeCollaborator
- Nanyang Central HospitalCollaborator
- Shenyang Pharmaceutical UniversityCollaborator
- Huangshi Central HospitalCollaborator
- No.2 People's Hospital of Fuyang CityCollaborator
- China Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.